For Conexeu specifically, the next investor checkpoints are clear — execution against the planned 510(k) submission in early 2027, advancement of the B.R.E.A.S.T.™ matrix and Ten Minute Tissue™ pipeline, and the expansion of the CXU™ platform across the multi-billion-dollar end markets the Company has flagged. For the broader regenerative-medicine tape, the message is even clearer. The week of May 21, 2026 looked, at first glance, like just another listing day. On closer inspection, it looked a lot more like the moment a category turned the page.